

# ForPatients

*by Roche*

Duchenne Muscular Dystrophy (DMD)

## Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

**Trial Status**  
Completed

**Trial Runs In**  
13 Countries

**Trial Identifier**  
NCT03039686  
2016-001654-18,WN40227  
CN001-016

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).

**Hoffmann-La Roche**  
Sponsor

**Phase 2/Phase 3**  
Phase

---

**NCT03039686 2016-001654-18,WN40227 CN001-016**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
Male

**Age**  
>=6 Years & <= 11 Years

**Healthy Volunteers**  
No

---